3 Biotech Stocks I'd Buy Right Now
It's been a banner year so far for biotech, but a handful of stocks have been travelling in the opposite direction of the iShares Nasdaq Biotechnology index. The industry-tracking index has risen about 26% this year, without the help of Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) or Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX). While these two underappreciated gems have been slipping, shares of Dynavax Technologies Corporation (NASDAQ: DVAX) have risen more than fourfold. Despite the massive run-up, I think there could be more upside for this vaccine developer.
Although these biotech stocks are surrounded by too much uncertainty to fit in my personal portfolio, bold investors could see big gains from each one over the long run. Here's a closer look.
These three biotech stocks deserve a thumbs-up right now. Image source: Getty Images.
Source: Fool.com
Dynavax Technologies Corp Aktie
Leichtes Buy-Überwiegen bei Dynavax Technologies Corp im Vergleich zu Sell-Einschätzungen.
Mit einem Community-Kursziel von 26 € für Dynavax Technologies Corp wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 9.91 € gesehen.
